--- title: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer nct_id: NCT00002858 overall_status: UNKNOWN phase: PHASE3 sponsor: Gustave Roussy, Cancer Campus, Grand Paris study_type: INTERVENTIONAL primary_condition: Lung Cancer countries: France canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00002858.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00002858" ct_last_update_post_date: 2009-02-09 last_seen_at: "2026-05-12T06:44:12.985Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer **Official Title:** PHASE III STUDY COMPARING TWO DOSES OF INDUCTION CHEMOTHERAPY FOLLOWED BY ALTERNATION OF CHEMOTHERAPY AND RADIOTHERAPY IN LIMITED SMALL CELL LUNG CANCER **NCT ID:** [NCT00002858](https://clinicaltrials.gov/study/NCT00002858) ## Key Facts - **Status:** UNKNOWN - **Phase:** PHASE3 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 280 - **Lead Sponsor:** Gustave Roussy, Cancer Campus, Grand Paris - **Conditions:** Lung Cancer - **Start Date:** 1993-03 - **CT.gov Last Update:** 2009-02-09 ## Brief Summary RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for small cell lung cancer. PURPOSE: Randomized phase III trial to study the effectiveness of combination chemotherapy using two different doses of cyclophosphamide followed by alternating chemotherapy and radiation therapy in treating patients with small cell lung cancer. ## Detailed Description OBJECTIVES: I. Compare the effect on 2-year disease-free survival of two different doses of cyclophosphamide as part of first induction chemotherapy followed by alternating chemotherapy and chest irradiation in patients with limited stage small cell lung cancer. OUTLINE: This is a randomized study. Patients are stratified by participating institution. All patients receive 2 courses of induction chemotherapy with doxorubicin, etoposide, cisplatin, and cyclophosphamide. For the first course, one group of patients receives a lower dose of cyclophosphamide than the other group. Both groups receive the same, and still lower, dose of cyclophosphamide during the second course. Beginning 1 week after the completion of induction therapy, patients receive 3 alternating courses each of radiotherapy to the mediastinal and supraclavicular areas delivered over 10-12 days and chemotherapy as in the second course of induction. Each course is initiated after a 1-week rest. Patients receive a final chemotherapy course beginning 4 weeks after the previous chemotherapy course. Patients are followed every 6 months for survival. PROJECTED ACCRUAL: A total of 280 patients will be entered. ## Eligibility - **Maximum age:** 69 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` DISEASE CHARACTERISTICS: Histologically proven small cell lung cancer with no distant metastases Size of initial lesion suitable for total irradiation Positive subclavicular nodes allowed No malignant pleural effusion No extension into contralateral lung PATIENT CHARACTERISTICS: Age: Under 70 Performance status: Karnofsky 60%-100% Hematopoietic: WBC greater than 2,000 Platelets greater than 125,000 Hepatic: Not specified Renal: Creatinine less than 1.1 mg/dL (100 micromoles/L) Cardiovascular: No myocardial infarction within 6 months No other cardiovascular disease that precludes protocol treatment Other: No hearing loss No prior or concurrent malignancy except: Basal cell skin carcinoma In situ carcinoma of the cervix Accessible for follow-up PRIOR CONCURRENT THERAPY: No prior chemotherapy, radiotherapy, or surgery ``` ## Interventions - **cisplatin** (DRUG) - **cyclophosphamide** (DRUG) - **doxorubicin hydrochloride** (DRUG) - **etoposide** (DRUG) - **radiation therapy** (RADIATION) ## Locations (19) - Centre Hospitalier Regional et Universitaire d'Angers, Angers, France - Centre Paul Papin, Angers, France - Institut Bergonie, Bordeaux, France - Centre Regional Francois Baclesse, Caen, France - Hopital Antoine Beclere, Clamart, France - Centre Hospitalier Sud Francilien - Site Corbeil, Corbeil, France - Hopital Intercommunal De Creteil, Créteil, France - Hopital De La Trouhade, Dijon, France - Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France - C.H. General Andre Boulloche, Montbéliard, France - CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France - Centre Antoine Lacassagne, Nice, France - Hopital Haut Leveque, Pessac, France - C.H. De Saumur, Saumur, France - Hopitaux Universitaire de Strasbourg, Strasbourg, France - Institut Claudius Regaud, Toulouse, France - Centre Alexis Vautrin, Vandœuvre-lès-Nancy, France - CHRU de Nancy - Hopitaux de Brabois, Vandœuvre-lès-Nancy, France - Institut Gustave Roussy, Villejuif, France ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.centre hospitalier regional et universitaire d'angers|angers||france` — added _(2026-05-12)_ - `locations.centre paul papin|angers||france` — added _(2026-05-12)_ - `locations.institut bergonie|bordeaux||france` — added _(2026-05-12)_ - `locations.centre regional francois baclesse|caen||france` — added _(2026-05-12)_ - `locations.hopital antoine beclere|clamart||france` — added _(2026-05-12)_ - `locations.centre hospitalier sud francilien - site corbeil|corbeil||france` — added _(2026-05-12)_ - `locations.hopital intercommunal de creteil|créteil||france` — added _(2026-05-12)_ - `locations.hopital de la trouhade|dijon||france` — added _(2026-05-12)_ - `locations.centre de lute contre le cancer,georges-francois leclerc|dijon||france` — added _(2026-05-12)_ - `locations.c.h. general andre boulloche|montbéliard||france` — added _(2026-05-12)_ - `locations.crlcc nantes - atlantique|nantes-saint herblain||france` — added _(2026-05-12)_ - `locations.centre antoine lacassagne|nice||france` — added _(2026-05-12)_ - `locations.hopital haut leveque|pessac||france` — added _(2026-05-12)_ - `locations.c.h. de saumur|saumur||france` — added _(2026-05-12)_ - `locations.hopitaux universitaire de strasbourg|strasbourg||france` — added _(2026-05-12)_ - `locations.institut claudius regaud|toulouse||france` — added _(2026-05-12)_ - `locations.centre alexis vautrin|vandœuvre-lès-nancy||france` — added _(2026-05-12)_ - `locations.chru de nancy - hopitaux de brabois|vandœuvre-lès-nancy||france` — added _(2026-05-12)_ - `locations.institut gustave roussy|villejuif||france` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT00002858.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT00002858* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*